Table of Contents
CHAPTER 1
INTRODUCTION
- 1.1 Cancer
- 1.2 The Immune System
- 1.3 Cancer Therapy and the Immune System: Focus of the Report
CHAPTER 2
REVIEW OF MAJOR CANCERS TARGETED BY IMMUNOTHERAPIES AND VACCINES
- 2.1 Breast Cancer
- Pathology
- Epidemiology
- Diagnosis
- 2.2 Colorectal Cancer
- Pathology
- Epidemiology
- Diagnosis
- 2.3 Lung Cancer
- Pathology
- Non-Small-Cell Lung Cancer
- Small-Cell Lung Cancer
- Epidemiology
- Diagnosis
- 2.4 Lymphoma
- Pathology of Non-Hodgkin' s Lymphoma
- Epidemiology of Lymphoma
- Diagnosis of Non-Hodgkin' s Lymphoma
- 2.5 Melanoma
- Pathology
- Epidemiology
- Diagnosis
- 2.6 Pancreatic Cancer
- Pathology
- Epidemiology
- Diagnosis
- 2.7 Prostate Cancer
- Pathology
- Epidemiology
- Diagnosis
- 2.8 Renal Cancer
- Pathology
- Epidemiology
- Diagnosis
- 2.9 R&D Challenges in the Development of Cancer Immunotherapies and
Vaccines
CHAPTER 3
CURRENT PHARMACOLOGICAL TREATMENT OPTIONS
- 3.1 Breast Cancer
- Chemotherapy
- Hormone Therapy
- Targeted Therapy: Herceptin
- 3.2 Colorectal Cancer
- Chemotherapy
- Targeted Therapy: Monoclonal Antibodies
- 3.3 Lung Cancer
- Chemotherapy (Non-Small-Cell Lung Cancer)
- Targeted Therapy: Kinase Inhibitors (Non-Small-Cell Lung Cancer)
- Photodynamic Therapy (Non-Small-Cell Lung Cancer)
- Chemotherapy (Small-Cell Lung Cancer)
- 3.4 Lymphoma
- Chemotherapy
- Monoclonal Antibodies
- Other Immuno-Based Therapies
- 3.5 Melanoma
- Interferon
- Interleukin 2
- Chemotherapy
- 3.6 Pancreatic Cancer
- Chemotherapy
- Targeted Therapy: Inhibition of Epidermal Growth Factor Receptor
Tyrosine Kinase
- 3.7 Prostate Cancer
- Luteinizing Hormone-Releasing Hormone Agonists
- Anti-androgens
- Chemotherapy
- 3.8 Renal Cancer
- Interferon
- Interleukin-2
- Targeted Therapy: Kinase Inhibitors
CHAPTER 4
CANCER IMMUNOTHERAPIES AND VACCINES IN DEVELOPMENT
- 4.1 New Approaches
- Non-Specific Active Immunotherapy (Immune Modulating Agents)
- Antigen Immunotherapies/Vaccines (Allogeneic)
- Autologous Antigen Immunotherapies/Vaccines
- Allogeneic Whole Tumor Cell Immunotherapies/Vaccines
- Autologous Whole Tumor Cell Immunotherapies/Vaccines
- Dendritic Cell Immunotherapies/Vaccines
- DNA and Viral Vector Vaccines
- 4.2 Setbacks
- 4.3 Breast Cancer
- Celldex Therapeutics
- GlaxoSmithKline
- Introgen Therapeutics
- Oxford BioMedica
- 4.4 Colorectal Cancer
- Celldex Therapeutics
- GenVec
- IDM Pharma
- Intracel
- Oxford BioMedica
- 4.5 Lung Cancer
- Active Biotech
- AVAX Technologies
- GlaxoSmithKline
- IDM Pharma
- Introgen Therapeutics
- Merck KGaA and Biomira
- NovaRx
- Pfizer and Coley Pharmaceutical
- Pharmexa
- Transgene
- 4.6 Lymphoma
- Biovest International
- Favrille
- Genitope
- Transgene
- 4.7 Melanoma
- Antigenics
- AVAX Technologies
- BioVex
- GenVec
- GlaxoSmithKline
- IDM Pharma
- Medarex and Bristol-Myers Squibb
- Merck KGaA
- Oxxon Therapeutics
- Pfizer
- Progenics Pharmaceuticals
- Vical
- 4.8 Pancreatic Cancer
- Celldex Therapeutics
- Cell Genesys
- GenVec
- GlobeImmune
- Lorus Therapeutics
- Pharmexa
- Receptor BioLogix
- 4.9 Prostate Cancer
- Cell Genesys
- Dendreon
- Northwest Biotherapeutics
- Oxford BioMedica
- 4.10 Renal Cancer
- Active Biotech
- Antigenics
- Argos Therapeutics
- Idera Pharmaceuticals
- Oxford BioMedica
CHAPTER 5.0
EXPERT INTERVIEWS - A VIRTUAL ROUNDTABLE
- Roman M. Chicz, PhD, Senior Vice President, Research and Development
- C. Richter King, PhD, Senior Vice President of Research
- Arthur M. Krieg, MD, Senior Vice President, Research and Development, and
Chief Scientific Officer
- Coley Pharmaceutical Group
- Christopher Nicodemus, MD, Senior Vice President, Research and Development
- Charles A. Nicolette, PhD, Vice President, Research and Development
- Peter K. Working, PhD, Senior Vice President, Research and Development
CHAPTER 6
COMPANY DIRECTORY WITH WEB ADDRESSES
References
Index
|
Related Report
|
View Cart
